UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Arthritis research & therapy, 2024-02, Vol.26 (1), p.49-49, Article 49

2024

Volltextzugriff (PDF)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatology and therapy, 2023-11, Vol.13 (11), p.2911-2916

2023

Volltextzugriff (PDF)

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry

The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2246601-2246601

2023

Volltextzugriff (PDF)

Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review

JEADV clinical practice, 2023-03, Vol.2 (1), p.5-18

2023

Volltextzugriff (PDF)

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

Dermatology and therapy, 2024-04, Vol.14 (4), p.933-952

2024

Volltextzugriff (PDF)

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

Dermatology and therapy, 2023-12, Vol.13 (12), p.3181-3191

2023

Volltextzugriff (PDF)

Two Cases of Lichen Striatus with Prolonged Active Phase

Pediatric dermatology, 2014-03, Vol.31 (2), p.e67-e68

2014

Volltextzugriff (PDF)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

JEADV clinical practice, 2023-06, Vol.2 (2), p.282-292

2023

Volltextzugriff (PDF)

Inappropriate application of nodule management guidelines in radiologist reports before and after revision of exclusion criteria

American journal of roentgenology (1976), 2011-05, Vol.196 (5), p.1115

2011

Volltextzugriff (PDF)

Cutaneous lymphatics and chronic lymphedema of the head and neck

Clinical anatomy (New York, N.Y.), 2012-01, Vol.25 (1), p.72-85

2012

Volltextzugriff (PDF)

43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB185-AB185

2023

Volltextzugriff (PDF)

43054 The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naïve and -experienced patients: A post-hoc analysis of patients receiving treatment according to US labels

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB237-AB237

2023

Volltextzugriff (PDF)

33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB174-AB174

2022

Volltextzugriff (PDF)

42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB191-AB191

2023

Volltextzugriff (PDF)

41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB12-AB12

2023

Volltextzugriff (PDF)

43113 Ixekizumab improves fatigue, an important patient-reported outcome in psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB59-AB59

2023

Volltextzugriff (PDF)

33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB180-AB180

2022

Volltextzugriff (PDF)

P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Skin (Milwood, N.Y.), 2023-11, Vol.7 (6), p.s232

2023

Volltextzugriff (PDF)

Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

Skin (Milwood, N.Y.), 2023-05, Vol.7 (3), p.s201

2023

Volltextzugriff (PDF)

Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective

Skin (Milwood, N.Y.), 2023-05, Vol.7 (3), p.s202

2023

Volltextzugriff (PDF)

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Drugs -- real world outcomes, 2024-06

2024

Volltextzugriff (PDF)

Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes

Dermatologic therapy, 2022-12, Vol.35 (12), p.e15954-n/a

2022

Volltextzugriff (PDF)

Novel psoriasis therapies and patient outcomes, part 2: biologic treatments

Cutis (New York, N.Y.), 2015-05, Vol.95 (5), p.282-290

2015

Volltextzugriff (PDF)

Novel psoriasis therapies and patient outcomes, part 1: topical medications

Cutis (New York, N.Y.), 2015-03, Vol.95 (3), p.164-170

2015

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Disease burden among patients with atopic dermatitis treated with systemic therapy for 4–12 months: results from the CorEvitas Atopic Dermatitis Registry

Prevalence, incidence and relative risk of cardiovascular disease risk factors in adults with atopic dermatitis: A systematic review

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

Two Cases of Lichen Striatus with Prolonged Active Phase

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)

Inappropriate application of nodule management guidelines in radiologist reports before and after revision of exclusion criteria

Cutaneous lymphatics and chronic lymphedema of the head and neck

43015 Ixekizumab real-world effectiveness at 24 weeks in patients with psoriasis: Data from the United States Taltz Customer Support Program

43054 The Psoriasis Study of Health Outcomes (PSoHO) in biologic-naïve and -experienced patients: A post-hoc analysis of patients receiving treatment according to US labels

33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study

42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events

41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials

43113 Ixekizumab improves fatigue, an important patient-reported outcome in psoriasis

33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada

P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program

Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective

Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long‐term efficacy and patient‐reported outcomes

Novel psoriasis therapies and patient outcomes, part 2: biologic treatments

Novel psoriasis therapies and patient outcomes, part 1: topical medications

Suchergebnisse filtern